-
Science|。 New concept: a systematic review of the treatment of cancer when refined
Time of Update: 2021-01-15
January 1, 2021, Aziz Sancar of the University of North Carolina and others published a review article on Science Online entitled "Clocks, cancer, and chronochemotherapy", which reviews the effects of clock interruptions on human health, especially the carcinogenic effects, and research efforts to improve cancer treatment through time-based therapy.
-
Related: Comparison of cardiovascular toxicity between cigarettes and e-cigarettes in adults
Time of Update: 2021-01-15
, there was no difference in inflammation and oxidative stress biomarkers among e-cigarette and non-smoking participants in the nationally representative adult population study.
Association of Cigarette and Electronic Cigarette Use Patterns With Levels of Inflammatory and Oxidative Stress Biomarkers Among US Adults: Population Assessment of Tobacco and Health Study.
-
Beijing Releases "Guidelines for Ethical Review of Clinical Research in CAR-T Cell Immunotherapy"
Time of Update: 2021-01-15
Research institutions and ethics committees require medical and health institutions to have the appropriate qualifications and conditions for conducting clinical research, and recommend that research projects have been completed and researched within the scope of the project, in accordance with the Code of Quality Management of Drug Clinical Trials (GCP), the Technical Guidelines for Research and Evaluation of Cell Therapy Products (Trial) (Trial) (2017), and the Measures for the Management of Stem Cell Clinical Research (Trial).
-
Acta Neuropathologica: Transparent cell meningioma is defined as a highly different DNA methylation spectrum and SMARCE1 mutation
Time of Update: 2021-01-15
In the study, the team described a molecularly different tumor substation, n-31, which was originally found in 3,093 meningoma queues through genome-wide DNA methylation screening, most of which were histologically diagnosed as transparent cell meningomas.
-
Nat Commun: Detection and analysis of circulating tumor DNA in tens of thousands of Chinese pan-cancer patients
Time of Update: 2021-01-15
the sensitivity of ctDNA testing for different cancers eliminated the CH mutation, ctDNA was detected in 73.5% of plasma samples, with the highest ctDNA detection rates for small cell lung cancer and prostate cancer (91.1% and 87.9%, respectively).
-
Sci Rep: Road transport workers are at higher risk of cancer
Time of Update: 2021-01-15
results showed that in the liver and liver bile tube cancer (SIR 1.15,95% CI 1.04-1.27), digestive organ cancer (SIR 1.28,95% CI 1.04-1.57), trachea, bronchid In terms of lung cancer (SIR 1.28, 95% CI 1.15-1.43) and bladder cancer (SIR 1.26, 95% CI 1.03-1.52), RTW's cancer incidence is significantly higher than that of government employees and the working population as a whole.
-
TP53 Mutant Bone Marrow Growth Abnormal Syndrome: Eprenetapopt did not reach the main endpoint of the Phase III study
Time of Update: 2021-01-15
A Phase III study of patients with TP53 mutant bone marrow growth syndrome has failed to reach the primary endpoint of its total remission (CR) rate, pharmaceutical company Aprea Therapeutics said recently.
but the eprenetapopt joint Aza cytosine group showed good tolerance, and the adverse event characteristics were similar to those of the Phase II trial.
-
China NMPA receives the NDA of Envafolimab (KN035) for the treatment of MSI-H/dMMR advanced solid tumors
Time of Update: 2021-01-15
Biopharmaceutical company TRACON announced today that China's State Drug Administration (NMPA) has accepted a new drug application (NDA) from Envafolimab (KN035) for the treatment of MSI-H/dMMR advanced solid tumors.
-
Guidelines for clinical application of new anti-tumor drugs (2020 edition), covering 9 major cancerous tumors and 83 drugs
Time of Update: 2021-01-15
II, the new anti-tumor drug guidelines involved in the new anti-tumor drugs mainly include: Part II of the clinical application of drug clinical application guidelines for systemic tumors respiratory tumor medication I, gyfytini Gefitinib preparations and specifications: tablets: 250 mg adaptation certificate: the topical growth factor (EGFR) gene with sensitive mutations of local late stage or metastasis non-small cell lung cancer (NSCLC).
-
Lancet oncology|。 Comparison of the effects of the first-line Durvalumab combined therapy for broad-stage small cell lung cancer
Time of Update: 2021-01-15
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
-
PNAS: At the bottom of the kettle, Jiang Xuejun's team confirmed that iron death is a powerful way to treat cancer
Time of Update: 2021-01-15
the team found that cancer cells often exhibit metabolic changes that make them susceptible to ferroptosis, a particular type of cell death, and found that a combination of drugs that block pi3K-AKT-mTOR and induce iron death can significantly damage and remove tumors.
-
Signal Transduct Target Ther: The team of Cai Xiujun of Zhejiang University has revealed new mechanisms for the transmission of drug-resistant cells targeted by exosome-mediated liver cancer
Time of Update: 2021-01-15
three important innovations from this outcome: (1) the first identification of circRNA-SORE, which plays a key role in soraphine resistance in liver cancer; (2) the first to reveal the ubibinic and degrading effects of PRP19 on YBX1; and (3) the first detection of intercellular transmission of sorafinib resistance in liver cancer mediated by exosome circRNA-SORE.
-
Annamycin treats soft tissue sarcoma, has been awarded FDA 'orphan drug title'
Time of Update: 2021-01-15
Drug Enforcement Administration (FDA) has awarded Annamycin the "Orphan Drug Title" (ODD) for the treatment of soft tissue sarcoma, the pharmaceutical company Moleculin Biotech announced today.
FDA recently allowed Moleculin to conduct phase IB/II clinical trials in the United States for patients with soft tissue sarcoma (STS) who have metasized to the lungs.
-
J Gastroenterol: Multi-target small molecule tyrosine kinase inhibitor Cabotinib is effective in treating advanced liver cancer
Time of Update: 2021-01-15
secondary endpoints include PFS, Total Lifetime (OS), Objective Mitigation Rate (ORR, Full/Partial Mitigation Best Response), Disease Control Rate (DCR, Objective Mitigation or Disease Stability), and Safety.
-
National Science Review: Breakthroughs . . The new strategy proposed by Liu Hongke/Zhao Jin/Guo Zijian has successfully achieved targeted anticancer drugs manufactured in tumors
Time of Update: 2021-01-15
Liu Hongke of Nanjing Normal University and Zhao Jin and Guo Zijian of Nanjing University jointly published a research paper entitled "Using bioorthogonally catalyzed fatality strategy to generate mit
-
Nat Med: Cancer cells can get worse when they spread to the liver, and the team reveals the reasons behind it and proposes treatments
Time of Update: 2021-01-15
study showed that hepatic metastasis tumors can use the host's external immune tolerance mechanism to develop access to immunotherapy resistance through the absence of CD8-T cells.
-
Nature Cancer: Non-small cell lung cancer immunotherapy effect prediction marker - HLA-B44 supertype
Time of Update: 2021-01-15
In addition, B44 was layered based on the presence of somatic cell mutations that cause negatively charged glutamate anchorage points, and it was determined that the benefits of immuno-checkpoint blocking therapy in patients with non-small cell lung cancer were similar to between melanoma.
-
Cell Biol Toxicol:S100A16 promotes pancreatic cancer metastasis through FGF19-mediated AKT and ERK1/2 paths
Time of Update: 2021-01-15
researchers also found that the S100A16 promotes the proliferation, migration and invasion of PDAC cells through akT and ERK1/2 signaling paths in a fibroblast growth factor 19 (FGF19) dependency.
-
Br J Haematol: Millions of people can't imagine that a Hodgkin's lymphoma patient contracted SARS-CoV-2 after the tumor subsided
Time of Update: 2021-01-15
sarah Challenor and David Tucker of the Department of Hematology at the Royal Cornwall Hospital in Truro, England, said in an article entitled "SARS-CoV-2-induced remission of Hodgkin lyoma" that a 61-year-old cancer patient had gradually subsided after recovering from COVID-19.
-
NMPA approves by BYVASDA (Bevadan antisimilar) for the treatment of relapsed glioblastoma
Time of Update: 2021-01-14
Biopharmaceutical company Innovent Biologics recently announced that BYVASDA® has been officially approved by China's State Drug Administration (NMPA) for the treatment of reocgenerative glioblastoma (GBM, the most common malignant primary brain tumor), which is byVASDA® in China's third adaptation.
